US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

214.03

-13.7200-6.02%

Volume:197.16K

Turnover:42.83M

Market Cap:540.32M

PE:- -

High:223.71

Open:220.01

Low:212.50

Close:227.75

52wk High:341.93

52wk Low:102.35

Shares:2.52M

Float Shares:2.52M

Volume Ratio:3.17

T/O Rate:7.81%

Dividend:0.91

Dividend Rate:0.43%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Newron presses on with Evenamide Phase 3 as FDA halts U.S. arm over safety signal

Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review

Noxopharm Says US FDA Feedback Supports Planned Phase II Trial Approach for Autoimmune Drug Candidate

MT Newswires Live

Top Executive Makes Major Move With Alignment Healthcare Stock

IHH Healthcare Looks Attractive on Recent Share Price Weakness

Imricor Medical Systems Says FDA Completes Review of PMA Module Three

MT Newswires Live

Imricor Clears Major FDA Hurdle on MR-Guided Ablation Platform

FDA feedback de-risks Noxopharm’s SOF-SKN Phase II trial plans

Healthcare Services expands via NEXDINE acquisition agreement

Health Care up on Defensive Bias

VTv Therapeutics Gets FDA Orphan Drug Designation for Sickle Cell Candidate

MT Newswires Live

Valneva Shrugs Off U.K. Revocation of Chikungunya Vaccine License

Fisher & Paykel Healthcare sets date for half‑year 2026 results

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

Vital Healthcare Property Trust Sharpens Governance After Internalisation

SCYNEXIS: Advancing Pipeline and Strong Funding Underpin Buy Rating; $32 Price Target Reaffirmed

Sector Update: Healthcare

MT Newswires Live

Exchange-Traded Funds Lower as US Equities Decline After Midday

MT Newswires Live

VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

New Abdominoplasty Trial Signals Steady Demand in Procedure-Driven Healthcare

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LABU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":214.03,"timestamp":1791468916349,"preClose":227.75,"halted":0,"volume":197210,"delay":0,"changeRate":-0.06024149286498353,"floatShares":2524486,"shares":2524486,"eps":0,"marketStatus":"Trading","change":-13.72,"latestTime":"10-08 10:15:16 EDT","open":220.01,"high":223.7074,"low":212.5,"amount":42829217.8249,"amplitude":0.049209,"askPrice":214.54,"askSize":30,"bidPrice":213.88,"bidSize":30,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":227.75,"sharesOutstanding":3074486,"nav":230.529,"aum":581967299.18,"dividendRate":0.004256,"bidAskSpread":0.002401,"preHourTrading":{"tag":"盘前","latestPrice":220.18,"preClose":227.75,"latestTime":"09:29 EDT","volume":6169,"amount":1385605.45651,"timestamp":1791466199999,"change":-7.57,"changeRate":-0.033238,"amplitude":0.038727},"postHourTrading":{"tag":"盘后","latestPrice":228.7,"preClose":227.75,"latestTime":"19:59 EDT","volume":2729,"amount":623483.6155,"timestamp":1791417573520,"change":0.95,"changeRate":0.004171,"amplitude":0.004911},"volumeRatio":3.170015,"impliedVol":0.9689,"impliedVolPercentile":0.7211},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2524486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.169211,"shares":2524486,"dividePrice":0.911,"high":223.7074,"amplitude":0.049209,"preClose":227.75,"low":212.5,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":214.03,"eps":0,"divideRate":0.004256,"volume":197160,"delay":0,"ttmEps":0,"open":220.01,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":249.65,"twentyDayClose":266,"sixtyDayClose":277.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673023380","title":"Newron presses on with Evenamide Phase 3 as FDA halts U.S. arm over safety signal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673023380","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673023380?lang=en_us&edition=fundamental","pubTime":"2026-10-08 13:34","pubTimestamp":1791437660,"startTime":"0","endTime":"0","summary":"Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has shared an announcement. Newron Pharmaceuticals said the U.S. FDA has issued a clinical hold on U.S. t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-evenamide-phase-3-as-fda-halts-u-s-arm-over-safety-signal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-evenamide-phase-3-as-fda-halts-u-s-arm-over-safety-signal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","BK4585","LABU","BK4588","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673023384","title":"Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review","url":"https://stock-news.laohu8.com/highlight/detail?id=2673023384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673023384?lang=en_us&edition=fundamental","pubTime":"2026-10-08 13:32","pubTimestamp":1791437568,"startTime":"0","endTime":"0","summary":"An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals has received a formal notification from the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-enigma-trs-program-as-fda-clinical-hold-prompts-safety-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-enigma-trs-program-as-fda-clinical-hold-prompts-safety-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBBQ","PSCH","PILL","LABU","BBC","PTH","BK4585","BIS","IBB","MEDX","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673044724","title":"Noxopharm Says US FDA Feedback Supports Planned Phase II Trial Approach for Autoimmune Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2673044724","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673044724?lang=en_us&edition=fundamental","pubTime":"2026-10-08 10:24","pubTimestamp":1791426258,"startTime":"0","endTime":"0","summary":"Noxopharm   said the US Food and Drug Administration has provided constructive feedback that was supportive of its planned approach for a phase II clinical trial for SOF-SKN, its autoimmune disease drug candidate, according to a Thursday Australian bourse filing.The company said the feedback provides increased regulatory clarity, and helps de-risk the drug candidate's development pathway, while it will incorporate the feedback into preparations for a future investigational new drug  submission that has the potential to increase SOF-SKN's commercial attractiveness.The phase II trial is targeted for the first half of calendar 2028, subject to regulatory, clinical and manufacturing requirements, it said.The company said an orphan drug designation opportunity exists for SOF-SKN, given there are no current targeted therapies.The company's shares fell nearly 2% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND.AU","IND","BK4585","LABU","BK7095","BK7067","BK7501","BK4588","NOX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673044473","title":"Top Executive Makes Major Move With Alignment Healthcare Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2673044473","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673044473?lang=en_us&edition=fundamental","pubTime":"2026-10-08 10:02","pubTimestamp":1791424972,"startTime":"0","endTime":"0","summary":"New insider activity at Alignment Healthcare ( ($ALHC) ) has taken place on October 7, 2026. Alignment Healthcare’s Chief Medical Officer, Hyong Ki...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-major-move-with-alignment-healthcare-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-major-move-with-alignment-healthcare-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4539","BK4588","BK4585","LABU","ALHC","BK4154","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049067","title":"IHH Healthcare Looks Attractive on Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049067","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673049067?lang=en_us&edition=fundamental","pubTime":"2026-10-08 09:08","pubTimestamp":1791421680,"startTime":"0","endTime":"0","summary":"0108 GMT - IHH Healthcare's recent share price weakness likely offers an attractive entry point, with earnings growth seen supported by more complex treatments, hospital expansions and Fortis-Gleneagles synergies, says Maybank IB analyst Nur Natasha Ariza in a note. Its focus on higher-value treatments and day-care services should also support growth beyond bed additions, she says. IHH's core net profit is expected to grow 18% annually over 2025-2028, faster than its 11% annual growth over 2016-2025, she reckons. Legal developments in its India operations provide little basis to revise earnings forecasts, in the analyst's view. Maybank maintains a buy rating on IHH and keeps its target price at 11.20 ringgit. Shares are unchanged at 7.90 ringgit.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4588","BK4585","LABU","LU0029874061.USD","BK4137","HCSG","LU0128526141.USD","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673046364","title":"Imricor Medical Systems Says FDA Completes Review of PMA Module Three","url":"https://stock-news.laohu8.com/highlight/detail?id=2673046364","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673046364?lang=en_us&edition=fundamental","pubTime":"2026-10-08 07:41","pubTimestamp":1791416498,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems  said the US Food and Drug Administration has completed its review of module three of the company's premarket approval  submission, which covers non-clinical bench testing for its Vision-MR ablation catheter 2.0, RF-5000 system and irrigation tubing set, according to a Thursday Australian bourse filing.No deficiencies were identified in the catheter or tubing set, while one deficiency was found in the RF-5000 system's third-party software operating system, which the company has already upgraded to a long-term supported version, per the filing.The company is preparing its response to the FDA, with module three expected to close upon acceptance and module four targeted for submission in November, thereby completing all PMA submissions, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7007","BK7503","LABU","PMA","BK4585","IMR.AU","BK4588","BK4129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673045533","title":"Imricor Clears Major FDA Hurdle on MR-Guided Ablation Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2673045533","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673045533?lang=en_us&edition=fundamental","pubTime":"2026-10-08 06:29","pubTimestamp":1791412149,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ). Imricor Medical Systems, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/imricor-clears-major-fda-hurdle-on-mr-guided-ablation-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/imricor-clears-major-fda-hurdle-on-mr-guided-ablation-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673404398","title":"FDA feedback de-risks Noxopharm’s SOF-SKN Phase II trial plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2673404398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673404398?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:30","pubTimestamp":1791408627,"startTime":"0","endTime":"0","summary":"Noxopharm Ltd. ( ($AU:NOX) ) just unveiled an update. Noxopharm has received supportive feedback from the U.S. Food and Drug Administration on its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-feedback-de-risks-noxopharms-sof-skn-phase-ii-trial-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-feedback-de-risks-noxopharms-sof-skn-phase-ii-trial-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SOF","BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673043623","title":"Healthcare Services expands via NEXDINE acquisition agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2673043623","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673043623?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:29","pubTimestamp":1791408544,"startTime":"0","endTime":"0","summary":"An update from Healthcare Services ( ($HCSG) ) is now available. On October 6, 2026, Healthcare Services Group, Inc. entered into an agreement to a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healthcare-services-expands-via-nexdine-acquisition-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healthcare-services-expands-via-nexdine-acquisition-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","HCSG","BK4585","XLV","LU0029874061.USD","BK4581","BK4137","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673043595","title":"Health Care up on Defensive Bias","url":"https://stock-news.laohu8.com/highlight/detail?id=2673043595","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673043595?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:24","pubTimestamp":1791408240,"startTime":"0","endTime":"0","summary":"Health-care companies rose amid deal activity and a rotation back into defensive sectors.An investment vehicle controlled by Canada's Weston family struck a deal to buy U.K. pharmacy chain Boots from investment firm Sycamore Partners for $8.9 billion including debt. Sycamore separated Boots from former owner Walgreens after a 2025 takeover.Merck shares fell after the Big Pharma company contended with a legal challenge to its Keytruda oncology drug in Europe. Following a ruling by a Dutch court in a case brought by Halozyme Therapeutics, alleging Merck used the company's MDASE technology, Merck was barred from selling an injectable form of Keytruda in eight European markets, including France, the Netherlands and Sweden.Becton Dickinson is doubling down on U.S. manufacturing not just to dodge future tariffs, but to strengthen increasingly fragile hospital supply chains, according to Chief Executive Tom Polen.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","TRUH","LU0289739343.SGD","SGXZ57979304.SGD","VHT","PAWZ","SG9999014559.SGD","SG9999014575.USD","LU0234572021.USD","IYH","XBI","SG9999014542.SGD","BK4533","LU0861579265.USD","XLV","LU0057025933.USD","LU0985320562.USD","LU0203347892.USD","PPH","IE00BLSP4452.SGD","FTXH","BK4534","BMED","FHLC","JDOC","LU0511384066.AUD","SG9999013999.USD","LU2491049909.HKD","LU2357627491.SGD","LU2023250843.SGD","IHE","MRK","LU1989771016.USD","SG9999001176.SGD","GDOC","LU0130102774.USD","LU1934455277.USD","LU2125909593.SGD","SG9999015341.SGD","HRTS","LU0965509101.SGD","BK4007","LU0203345920.USD","IE00BJT1NW94.SGD","RXL","LABU","LU1093756168.USD","LU0162691827.USD","LU0965509283.SGD","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048124","title":"VTv Therapeutics Gets FDA Orphan Drug Designation for Sickle Cell Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048124","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048124?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:53","pubTimestamp":1791406430,"startTime":"0","endTime":"0","summary":"VTv Therapeutics (VTVT) said the US Food and Drug Administration granted orphan drug designation to HPPD, its investigational oral treatment for sickle cell disease.Preclinical studies conducted at Au","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4588","LENZ","BK4585","VTVT","LABU","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048653","title":"Valneva Shrugs Off U.K. Revocation of Chikungunya Vaccine License","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048653","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048653?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:33","pubTimestamp":1791405206,"startTime":"0","endTime":"0","summary":"An update from Valneva ( ($FR:VLA) ) is now available. Valneva said the U.K. Medicines and Healthcare products Regulatory Agency has revoked the ma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/valneva-shrugs-off-u-k-revocation-of-chikungunya-vaccine-license?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/valneva-shrugs-off-u-k-revocation-of-chikungunya-vaccine-license?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","XLV","BK4585","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048621","title":"Fisher & Paykel Healthcare sets date for half‑year 2026 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048621","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048621?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:17","pubTimestamp":1791404255,"startTime":"0","endTime":"0","summary":"The latest update is out from Fisher & Paykel Healthcare Corporation Limited ( ($NZ:FPH) ). Fisher & Paykel Healthcare has scheduled the release of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fisher-paykel-healthcare-sets-date-for-halfyear-2026-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fisher-paykel-healthcare-sets-date-for-halfyear-2026-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XLV","XBI","BK8004","LABU","FPH.NZ","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673010917","title":"vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673010917","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673010917?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:01","pubTimestamp":1791403260,"startTime":"0","endTime":"0","summary":"Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatinHIGH POINT, N.C., Oct.  07, 2026 (GLOBE NEWSWI","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376824/0/en/vtv-therapeutics-announces-fda-orphan-drug-designation-for-hppd-in-sickle-cell-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","VTVT","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673618010","title":"Vital Healthcare Property Trust Sharpens Governance After Internalisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673618010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673618010?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:47","pubTimestamp":1791402455,"startTime":"0","endTime":"0","summary":"Vital Healthcare Property ( ($NZ:VHP) ) has shared an update. Vital Healthcare Property Trust is undertaking an investor governance roadshow to upd...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vital-healthcare-property-trust-sharpens-governance-after-internalisation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vital-healthcare-property-trust-sharpens-governance-after-internalisation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VHP.NZ","XLV","BK8073","XBI","BK8059","BK4588","BK4581","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673012046","title":"SCYNEXIS: Advancing Pipeline and Strong Funding Underpin Buy Rating; $32 Price Target Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2673012046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673012046?lang=en_us&edition=fundamental","pubTime":"2026-10-08 02:05","pubTimestamp":1791396325,"startTime":"0","endTime":"0","summary":"SCYNEXIS, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/scynexis-advancing-pipeline-and-strong-funding-underpin-buy-rating-32-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/scynexis-advancing-pipeline-and-strong-funding-underpin-buy-rating-32-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4581","XLV","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014593","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014593","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673014593?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:10","pubTimestamp":1791393056,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State Street Health Care Select Sector SPDR ETF  advancing 1.7%.The iShares Biotechnology ETF  increased 0.8%.In corporate news, Halozyme Therapeutics  shares rose 1.8% after the company said it has been awarded an injunction by the specialized Dutch patent court in The Hague that stops manufacture and sale of Merck's  Keytruda SC in multiple European markets. Merck shares were up 1%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","LU0648001328.SGD","BK4588","LU0098860793.USD","LU2461242641.AUD","SG9999015358.SGD","LU0106261372.USD","LU2125909247.SGD","LU2125909593.SGD","LU2125154778.USD","LU1035773651.USD","LU1066051498.USD","LU2491049909.HKD","LU0289961442.SGD","LU0122379950.USD","LU0868494617.USD","BK4581","LU0265550946.USD","IE0002141913.USD","SG9999013999.USD","LU1989772840.SGD","RXL","LU1023059063.AUD","LU2361044865.SGD","LU0511384066.AUD","LU1941712264.USD","LU0289739343.SGD","LU0965509283.SGD","IE00BLSP4239.USD","LU2125154935.USD","LU0861579265.USD","BK4550","LU0058720904.USD","LU0472753341.HKD","IE00BBT3K403.USD","LU2468319806.SGD","XLV","LU1917777945.USD","IE0009355771.USD","LU0208291251.USD","LU1093756325.SGD","LU2491050154.USD","IE00BLSP4452.SGD","LU0234572021.USD","FFOX","GDOC","HRTS","LU2324357040.USD","LU1061106388.HKD","LU0238689110.USD","LU0965509101.SGD","IHE","LU0965508806.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","IE00BN8TJ469.HKD","BK4007","FHLC","PPH","IE00B4R5TH58.HKD","LU0203347892.USD","LU1934455277.USD","TRUH","HALO","LU0069063385.USD","PAWZ","LU1989772923.USD","LU1066051225.USD","LU1983299246.USD","LU0320765646.SGD","IE00B1BXHZ80.USD","LU2112291526.USD","BK4534","LU2106854487.HKD","SG9999001176.USD","SG9999001440.SGD","BK4559","LU1069347547.HKD","LU0072461881.USD","LU0070302665.USD","IE00BJT1NW94.SGD","LU1974910355.USD","LU2023250504.SGD","LU0211331839.USD","LU1585245621.USD","BK4585","SG9999002224.SGD","LU1093756168.USD","LU1941712348.USD","BMED","SG9999014542.SGD","SG9999001176.SGD","LU0006306889.USD","LU0057025933.USD","LU1037948897.HKD","XBI","LU2357627491.SGD","LU2417539215.USD","BK4516","LU2456880835.USD","SGXZ57979304.SGD","LU1032466523.USD","SG9999002232.USD","LU0265550359.USD","LU0266013472.USD","SG9999014575.USD","SG9999014567.USD","LU2491050071.SGD","LU0320765489.SGD","LU0130102774.USD","LU0868494708.USD","LU1430594728.SGD","LU1037948541.HKD","LU2089984988.USD","LU2360032135.SGD","BK4139","IE000M9KFDE8.USD","LU0162691827.USD","LU0203345920.USD","LU0985320562.USD","LU1057294990.SGD","LU0689626769.HKD","LU0053671581.USD","LU0980610538.SGD","LU0859254822.USD","LU1699723380.USD","LU0942090050.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU1201861249.SGD","LU2023250843.SGD","LU0477156953.USD","MRK","LU1934455863.HKD","SG9999015341.SGD","LU0130517989.USD","LU0965509010.AUD","LU1162221912.USD","LU1116320901.HKD","LU0823416689.USD","LU2361044949.HKD","IE00B2B36J28.USD","LU1116320737.USD","LU0124676726.USD","IYH","LU1989771016.USD","LU1571399168.USD","LU2433249047.HKD","FTXH","LU0289739699.SGD","LU1066053197.SGD","SG9999014559.SGD","JDOC","LU1923622614.USD","LABU","LU2361045086.USD","LU1929549753.HKD","LU1066051811.HKD","LU2236285917.USD","LU1934455194.USD","IXJ","LU0432979614.USD","VHT","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673401459","title":"Exchange-Traded Funds Lower as US Equities Decline After Midday","url":"https://stock-news.laohu8.com/highlight/detail?id=2673401459","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673401459?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:10","pubTimestamp":1791393012,"startTime":"0","endTime":"0","summary":"Broad Market IndicatorsBroad-market exchange-traded funds IWM and IVV fell. Actively traded Invesco QQQ Trust (QQQ) eased 0.4%.US equity indexes fell ahead of the release of the Federal Reserve's Sept","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHNY","XLV","CBOJ","XLPU","GBTC","USO","IYH","GLDY","BK4588","TECL","CBOY","VHT","XLY","BK4550","BTCI","USG","DEFI","BPI","KGLD","IYE","QQQ","SCO","IBB","SGOL","DGP","CBTO","BTC.USD.CC","VIS","QDEC","IBIT","MNRS","PSQ","NOCT","BTCW","ETQ","BK4504","CBXJ","BGLD","UNG","BITX","GLDM","CBTJ","XLF","AGQ","FAS","SIVR","DZZ","IGLD","XLP","SETH","QQQX","BETH","BTRN","RETL","BITB","EZBC","ETH.USD.CC","BITO","IGM","XLK","QID","GPIQ","TQQY","BK4570","BK4585","BTCC","GLD","ETH","ETHD","IYW","GLL","OUNZ","CBTY","XAUUSD.FOREX","BTCO","ESK","BCCC","BK4561","FBTC","HODL","CBOA","QLD","FGDL","EETH","CBXY","CBTA","XBTY","NJAN","SQQQ","NDX","YBTC","YGLD","CBXO","ETHT","BK4593","BTC","DGZ","ARKB","LABU","CBXA","FAZ","DFII","SLV","IAUM","QQQM","XAGUSD.FOREX","XLE","RTH","ZSL","BK4534","XLPD","BTF","XLI","SOXL","IAUI","CBOO","IYJ","BITY","NJUL","BFJL","BAR","SOXX","IAU","BTCL","UCO","VDC","BFAP","SOXS","UGL","XBI","TETH","TQQQ","BITU","BK4581","BETE","BAGY","MAXI","BITI","NAPR","QMAR","BRRR","ETCO","BTCZ","XRT","AAAU","QBF","SBIT","DULL","BK4547","XSD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014180","title":"VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673014180?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:00","pubTimestamp":1791392422,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, October 7th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA), a developer of next-generation antibody-based cancer the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NDX","BK4139","JEPQ","BK4588","XBI","NVIW.SI","NQmain","TQQQ","LABU","BK4581","QYLG","QQQ","QID","GPIQ","TQQY","QQQM",".IXIC","BK4585","MNQmain","FTEC","PSQ","QQQA","QDTE","QQQE","03086","TECS","QQQJ","QLD","VRXA","SQQQ","QQQY","IYW","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011717","title":"New Abdominoplasty Trial Signals Steady Demand in Procedure-Driven Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011717?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390623,"startTime":"0","endTime":"0","summary":"Lam Research Corp ($LRCX) announced an update on their ongoing clinical study. The study, formally titled “Prospective One-Year Evaluation of the S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/new-abdominoplasty-trial-signals-steady-demand-in-procedure-driven-healthcare?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/new-abdominoplasty-trial-signals-steady-demand-in-procedure-driven-healthcare?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0210536198.USD","KNOW","QQQG","LU1066053197.SGD","LRCX","HCSG","LU0942090050.USD","LU0061474960.USD","LU2244417387.USD","IETC","XLV","BK4137","IE00BJJMRY28.SGD","LU0868494708.USD","LU2931357623.SGD","XBI","LU1992135399.USD","EPAI","BOBP","LU1974910355.USD","RDVY","COWG","LU0320765059.SGD","LU2089985449.USD","LU0157215616.USD","CLSE","LU0187121727.USD","RDVI","LU1244550221.USD","TINY","BAI","LRCU","LU0672654240.SGD","IE00B1XK9C88.USD","LU1066051811.HKD","LU1496350502.SGD","LU1674673691.USD","PSI","BK4588","LABU","TEK","IE00BQXX3C00.GBP","LRCC","RULE","LU1548497426.USD","TDV","ABFL","BK4543","BK4581","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":2,"totalSize":420,"code":"91000000","status":"200"}]}}